Earnings ·
Zentalis Pharmaceuticals reported second quarter 2026 financial results on August 6, 2026
ZNTLZentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals reported second quarter 2026 financial results on August 6, 2026. The company held $174.6 million in cash, cash equivalents, and marketable securities as of June 30, 2026, providing a runway into late 2027. Total operating expenses were $44.4 million for the quarter, compared to $36.1 million in the prior year period. Research and development expenses increased to $35.2 million from $27.6 million, driven by a $7.0 million milestone payment to Recurium IP Holdings LLC upon commencement of the Phase 3 ASPENOVA trial. The company announced that enrollment is complete for DENALI Parts 2a and 2b, with Part 2c currently enrolling. Topline data from the registration-intended DENALI Part 2 study is expected in the first half of 2027 to support a potential accelerated approval strategy. Zentalis Pharmaceuticals operates as a clinical oncology innovator developing azenosertib, an investigational WEE1 inhibitor for ovarian cancer.